NFKB1 and cancer: NFκB that is constitutively active in a large proportion of cancers and is bound to its inhibitor IκB within the cytoplasm, and inhibition of proteasome activity prevents degradation of IκB and subsequent activation and translocation of NFκB to the nucleus.